Holdings, Inc Announces Financing Agreement with Yorkville Advisors Global, LP of up to $11.2 Million
Summary
Cardio Diagnostics Holdings, Inc (the Company) (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that it has entered into a securities purchase agreement (Securities Purchase Agreement) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (Yorkville), under which the Company agreed to sell and issue to Yorkville convertible debentures (Convertible Debentures) in a gross aggregate principal amount of up to $11.2 million (Subscription Amount). This investment will help expand the reach of our cutting-edge tests, accelerating our mission to transform heart disease prevention and early detection. We are confident that these initiatives will drive significant value for our customers and stakeholders.Northland Capital Markets acted as the sole placement agent on the transaction.Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.This press release includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.